A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies
Bi-specific T-cell engager antibodies (BiTEs) are synthetic fusion molecules that combine multiple antibody-binding domains to induce active contact between T-cells and antigen expressing cells in the body. Blinatumomab, a CD19-CD3 BiTE is now a widely used therapy for relapsed B-cell malignancies,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286961/?tool=EBI |
| _version_ | 1797796007993409536 |
|---|---|
| author | Alex Shepherd Bigitha Bennychen Anne Marcil Darin Bloemberg Robert A. Pon Risini D. Weeratna Scott McComb |
| author_facet | Alex Shepherd Bigitha Bennychen Anne Marcil Darin Bloemberg Robert A. Pon Risini D. Weeratna Scott McComb |
| author_sort | Alex Shepherd |
| collection | DOAJ |
| description | Bi-specific T-cell engager antibodies (BiTEs) are synthetic fusion molecules that combine multiple antibody-binding domains to induce active contact between T-cells and antigen expressing cells in the body. Blinatumomab, a CD19-CD3 BiTE is now a widely used therapy for relapsed B-cell malignancies, and similar BiTE therapeutics have shown promise for treating various other forms of cancer. The current process for new BiTE development is time consuming and costly, requiring characterization of the individual antigen binding domains, followed by bi-specific design, protein production, purification, and eventually functional screening. Here, we sought to establish a more cost-efficient approach for generating novel BiTE sequences and assessing bioactivity through a function first approach without purification. We generate a plasmid with a bi-modular structure to allow high-throughput exchange of either binding arm, enabling rapid screening of novel tumour-targeting single chain variable (scFv) domains in combination with the well-characterized OKT3 scFv CD3-targeting domain. We also demonstrate two systems for high throughput functional screening of BiTE proteins based on Jurkat T cells (referred to as BiTE-J). Using BiTE-J we evaluate four EGFRvIII-scFv sequenced in BiTE format, identifying two constructs with superior activity for redirecting T-cells against the EGFRvIII-tumour specific antigen. We also confirm activity in primary T cells, where novel EGFRvIII-BiTEs induced T cell activation and antigen selective tumor killing. We finally demonstrate similar exchange the CD3-interacting element of our bi-modular plasmid. By testing several novel CD3-targeting scFv elements for activity in EGFRvIII-targeted BiTEs, we were able to identify highly active BiTE molecules with desirable functional activity for downstream development. In summary, BiTE-J presents a low cost, high-throughput method for the rapid assessment of novel BiTE molecules without the need for purification and quantification. |
| first_indexed | 2024-03-13T03:27:40Z |
| format | Article |
| id | doaj.art-b963816902bb40d5ba44061d2e1b1911 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-13T03:27:40Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-b963816902bb40d5ba44061d2e1b19112023-06-25T05:31:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01186A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodiesAlex ShepherdBigitha BennychenAnne MarcilDarin BloembergRobert A. PonRisini D. WeeratnaScott McCombBi-specific T-cell engager antibodies (BiTEs) are synthetic fusion molecules that combine multiple antibody-binding domains to induce active contact between T-cells and antigen expressing cells in the body. Blinatumomab, a CD19-CD3 BiTE is now a widely used therapy for relapsed B-cell malignancies, and similar BiTE therapeutics have shown promise for treating various other forms of cancer. The current process for new BiTE development is time consuming and costly, requiring characterization of the individual antigen binding domains, followed by bi-specific design, protein production, purification, and eventually functional screening. Here, we sought to establish a more cost-efficient approach for generating novel BiTE sequences and assessing bioactivity through a function first approach without purification. We generate a plasmid with a bi-modular structure to allow high-throughput exchange of either binding arm, enabling rapid screening of novel tumour-targeting single chain variable (scFv) domains in combination with the well-characterized OKT3 scFv CD3-targeting domain. We also demonstrate two systems for high throughput functional screening of BiTE proteins based on Jurkat T cells (referred to as BiTE-J). Using BiTE-J we evaluate four EGFRvIII-scFv sequenced in BiTE format, identifying two constructs with superior activity for redirecting T-cells against the EGFRvIII-tumour specific antigen. We also confirm activity in primary T cells, where novel EGFRvIII-BiTEs induced T cell activation and antigen selective tumor killing. We finally demonstrate similar exchange the CD3-interacting element of our bi-modular plasmid. By testing several novel CD3-targeting scFv elements for activity in EGFRvIII-targeted BiTEs, we were able to identify highly active BiTE molecules with desirable functional activity for downstream development. In summary, BiTE-J presents a low cost, high-throughput method for the rapid assessment of novel BiTE molecules without the need for purification and quantification.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286961/?tool=EBI |
| spellingShingle | Alex Shepherd Bigitha Bennychen Anne Marcil Darin Bloemberg Robert A. Pon Risini D. Weeratna Scott McComb A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies PLoS ONE |
| title | A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies |
| title_full | A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies |
| title_fullStr | A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies |
| title_full_unstemmed | A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies |
| title_short | A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies |
| title_sort | simplified function first method for the discovery and optimization of bispecific immune engaging antibodies |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286961/?tool=EBI |
| work_keys_str_mv | AT alexshepherd asimplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT bigithabennychen asimplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT annemarcil asimplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT darinbloemberg asimplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT robertapon asimplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT risinidweeratna asimplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT scottmccomb asimplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT alexshepherd simplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT bigithabennychen simplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT annemarcil simplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT darinbloemberg simplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT robertapon simplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT risinidweeratna simplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies AT scottmccomb simplifiedfunctionfirstmethodforthediscoveryandoptimizationofbispecificimmuneengagingantibodies |